Zoledronate is a drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. Also called zoledronic acid and Zometa.
Some of the principal treatments for osteoporosis, denosumab, zoledronate and calcium, could have a protective effect against COVID-19 in patients who take them, specifically a 30 to 40% reduction in the rate of infection, according to the results of a joint study by Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University and the Pere Virgili Health Park.
Oxytocin, produced by the hypothalamus and sometimes known as the "love hormone" for its involvement in pair bonding and orgasm, can be a strong ally in the control and prevention of osteoporosis, according to a study by scientists at São Paulo State University in Brazil.
Researchers have created fruit fly “avatars” that have helped to guide treatment for a man who had terminal colon cancer.
USC researchers and collaborators report a breakthrough to prevent damage to the jaw, a side effect suffered by some people undergoing treatment for cancer or osteoporosis.
Imagine pain in an arm or leg so intense that the sufferer would rather undergo an amputation than put up with it any longer. For those with complex regional pain syndrome (CRPS), this is not just a hypothetical nightmare—it is reality.
Stem cells can be protected from the effects of ageing by a drug currently used to treat patients with osteoporosis, a breakthrough study has found.
A class of drugs widely used to treat osteoporosis appears to impede a cell's ability to repair a protective outer membrane that helps determine what enters and exits, researchers report.
Researchers have identified a range of factors that are associated with the likelihood that a patient with advanced lung cancer will develop bone metastases or skeletal-related events.
Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
St George's, University of London research has found that a drug normally given to osteoporosis sufferers could provide effective pain relief to patients with knee and hip osteoarthritis.
A chemically altered osteoporosis drug may be useful in fighting malaria, researchers report in a new study. Unlike similar compounds tested against other parasitic protozoa, the drug readily crosses into the red blood cells of malaria-infected mice and kills the malaria parasite. The drug works at very low concentrations with no observed toxicity to the mouse.
A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds.
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.
Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.